David K. Kim, MD; Carolyn B. Bridges, MD; Kathleen H. Harriman, PhD, MPH, RN; on behalf of the Advisory Committee on Immunization Practices †
Disclosures: To assure the integrity of the ACIP, the U.S. Department of Health and Human Services has taken steps to ensure that there is technical adherence to ethics statutes and regulations regarding financial conflicts of interest. Concerns regarding the potential for the appearance of a conflict are addressed, or avoided altogether, through pre- and post-appointment considerations. Individuals with particular vaccine-related interests will not be considered for appointment to the committee. Potential nominees are screened for conflicts of interest and, if any are found, they are asked to divest or forgo certain vaccine-related activities. In addition, at the beginning of each ACIP meeting, each member is asked to declare his or her conflicts. Members with conflicts are not permitted to vote if the conflict involves the vaccine or biological being voted on. Details can be found at www.cdc.gov/vaccines/acip/committee/structure-role.html. Drs. Kim, Bridges, and Harriman authored this work. Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?ms Num=M14-2755.
Corresponding Author: David K. Kim, MD, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop A-19, Atlanta, GA 30333; e-mail, email@example.com.
Current Author Addresses: Dr. Kim: Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop A-19, Atlanta, GA 30333.
Dr. Bridges: Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop A-19, Atlanta, GA 30333.
Dr. Harriman: California Department of Public Health, 850 Marina Bay Parkway, Building P, Second Floor, Richmond, CA 94804.
Author Contributions: Conception and design: D.K. Kim, C.B. Bridges.
Drafting of the article: D.K. Kim.
Critical revision of the article for important intellectual content: D.K. Kim, C.B. Bridges, K.H. Harriman.
Final approval of the article: D.K. Kim, C.B. Bridges, K.H. Harriman.
Administrative, technical, or logistic support: D.K. Kim, C.B. Bridges.
Collection and assembly of data: D.K. Kim.
Recommended adult immunization schedule, by vaccine and age group, for adults aged 19 years or older: United States, 2015.
Vaccines that might be indicated for adults aged 19 years or older, based on medical and other indications: United States, 2015.
Footnotes to the recommended adult immunization schedule for adults aged 19 years or older: United States, 2015.
Table 1. Contraindications and Precautions for Commonly Used Vaccines in Adults*†‡
Recommended pneumococcal vaccination schedule and intervals, by age, health condition, and other risks.
The dashed line represents the interval between the two PPSV23 doses. PCV13 = 13-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine.
* Chronic health conditions are defined as chronic heart disease (including congestive heart failure and cardiomyopathies, excluding hypertension), chronic lung disease (including chronic obstructive lung disease, emphysema, and asthma), chronic liver disease (including cirrhosis), alcoholism, or diabetes mellitus.
† Immunocompromising conditions are defined as congenital or acquired immunodeficiency (including B- or T-lymphocyte deficiency, complement deficiencies, and phagocytic disorders excluding chronic granulomatous disease), HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancy, multiple myeloma, solid organ transplant, and iatrogenic immunosuppression (including long-term systemic corticosteroids and radiation therapy).
‡ Anatomical or functional asplenia is defined as sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia, splenic dysfunction, and splenectomy.
§ Administer PPSV23 as soon as possible if the 6- to 12-month time window has passed.
Table 2. Pneumococcal Vaccination Recommendations, by Patient Age, Health Condition, Pneumococcal Vaccination History, and Other Risks
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Kim DK, Bridges CB, Harriman KH, on behalf of the Advisory Committee on Immunization Practices. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2015*. Ann Intern Med. ;162:214–223. doi: 10.7326/M14-2755
Download citation file:
Published: Ann Intern Med. 2015;162(3):214-223.
Guidelines, Infectious Disease, Prevention/Screening, Vaccines/Immunization.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use